Publications dans lesquelles il/elle collabore avec José Cabeza Barrera (26)

2024

  1. Comprehensive physicochemical and functional analysis of pembrolizumab based on controlled degradation studies: Impact on antigen–antibody binding

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 194, pp. 131-147

2023

  1. Analysing the In-Use Stability of mRNA-LNP COVID-19 Vaccines Comirnaty™ (Pfizer) and Spikevax™ (Moderna): A Comparative Study of the Particulate

    Vaccines, Vol. 11, Núm. 11

  2. Comprehensive physicochemical characterization of a peptide-based medicine: Teduglutide (Revestive®) structural description and stress testing

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 184, pp. 103-115

2022

  1. Combined use of UV and MS data for ICH Stability-Indication Method: Quantification and isoforms identification of intact nivolumab

    Microchemical Journal, Vol. 182

  2. Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress

    Pharmaceutics, Vol. 14, Núm. 4

  3. Degradation and in-use stability study of five marketed therapeutic monoclonal antibodies by generic weak cation exchange liquid chromatographic method ((WCX)HPLC/DAD)

    Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 1203

  4. Method for identification and quantification of intact teduglutide peptide using (RP)UHPLC-UV-(HESI/ORBITRAP)MS

    Analytical Methods, Vol. 14, Núm. 43, pp. 4359-4369

  5. Tracking the physicochemical stability of teduglutide (Revestive®) clinical solutions over time in different storage containers

    Journal of Pharmaceutical and Biomedical Analysis, Vol. 221

2021

  1. Stability study over time of clinical solutions of ziv-aflibercept prepared in infusion bags using a proper combination of physicochemical and functional strategies

    Journal of Pharmaceutical and Biomedical Analysis, Vol. 203

  2. The relevance of monoclonal antibodies in the treatment of COVID-19

    Vaccines, Vol. 9, Núm. 6

2020

  1. Comprehensive biophysical and functional study of ziv-aflibercept: characterization and forced degradation

    Scientific Reports, Vol. 10, Núm. 1

  2. Intact charge variant analysis of ziv-aflibercept by cationic exchange liquid chromatography as a proof of concept: Comparison between volatile and non-volatile salts in the mobile phase

    Journal of Pharmaceutical and Biomedical Analysis, Vol. 185

  3. Use of subcutaneous tocilizumab to prepare intravenous solutions for COVID-19 emergency shortage: Comparative analytical study of physicochemical quality attributes

    Journal of Pharmaceutical Analysis, Vol. 10, Núm. 6, pp. 532-545

2019

  1. Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA)

    BioDrugs, Vol. 33, Núm. 2, pp. 193-205

2018

  1. Study of aggregation in therapeutic monoclonal antibodies subjected to stress and long-term stability tests by analyzing size exclusion liquid chromatographic profiles

    International Journal of Biological Macromolecules, Vol. 118, pp. 511-524

  2. Validated reverse phase HPLC diode array method for the quantification of intact bevacizumab, infliximab and trastuzumab for long-term stability study

    International Journal of Biological Macromolecules, Vol. 116, pp. 993-1003

2016

  1. Development and use of specific ELISA methods for quantifying the biological activity of bevacizumab, cetuximab and trastuzumab in stability studies

    Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 1032, pp. 155-164

  2. Study and ICH validation of a reverse-phase liquid chromatographic method for the quantification of the intact monoclonal antibody cetuximab

    Journal of Pharmaceutical Analysis, Vol. 6, Núm. 2, pp. 117-124

  3. The Effects of Light-Accelerated Degradation on the Aggregation of Marketed Therapeutic Monoclonal Antibodies Evaluated by Size-Exclusion Chromatography with Diode Array Detection

    Journal of Pharmaceutical Sciences, Vol. 105, Núm. 4, pp. 1405-1418

2015

  1. Cluster-based comparison of the peptide mass fingerprint obtained by MALDI-TOF mass spectrometry. A case study: Long-term stability of rituximab

    Analyst, Vol. 140, Núm. 5, pp. 1717-1730